- Clinical Trials
- April 2024
- 60 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- January 2022
- 200 Pages
Global
From €7206EUR$7,500USD£6,186GBP
- Report
- January 2022
- 60 Pages
Global
From €3795EUR$3,950USD£3,258GBP
- Report
- June 2020
- 112 Pages
Global
From €4564EUR$4,750USD£3,918GBP
- Report
- August 2022
Global
From €1047EUR$1,090USD£899GBP
- Report
- February 2021
Global
From €2844EUR$2,960USD£2,442GBP
- Drug Pipelines
- March 2021
Global
From €2402EUR$2,500USD£2,062GBP
- Drug Pipelines
- July 2020
- 440 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- January 2024
- 109 Pages
Global
From €3500EUR$3,902USD£3,110GBP
The Traumatic Brain Injury Drug market is a subset of the Central Nervous System Drugs market. It is composed of drugs used to treat the physical and psychological effects of traumatic brain injuries (TBIs). These drugs are used to reduce inflammation, improve cognitive function, and reduce the risk of secondary injury. Commonly used drugs include corticosteroids, anticonvulsants, and antidepressants. Additionally, some drugs are used to treat the psychological effects of TBIs, such as anxiety, depression, and post-traumatic stress disorder.
The Traumatic Brain Injury Drug market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Pfizer, Novartis, Merck, Johnson & Johnson, and GlaxoSmithKline. Other companies include Sanofi, AstraZeneca, and Eli Lilly. Show Less Read more
